Last updated: May 29, 2026

Application No. 17/909,358

GUIDANCE AND NAVIGATION CONTROL (GNC) ANTIBODY-LIKE PROTEINSAND METHODS OF MAKING AND USING THEREOF

Non-Final OA

Filed

Sep 02, 2022

Priority

Mar 17, 2020 — provisional 62/991,042 +2 more

Examiner

DRISCOLL, MAUREEN VARINA

Art Unit

1644

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.

OA Round

1 (Non-Final)

Interview Optional

— +35.3% interview lift. Examiner has a relatively high allowance rate (68%); +35.3% interview lift. A written response may suffice.

Based on 75 resolved cases, 2023–2026

Examiner Intelligence

DRISCOLL, MAUREEN VARINA View full profile →

Grants 68% — above average

Career Allowance Rate

51 granted / 75 resolved

+8.0% vs TC avg

Strong +35% interview lift

Without

With

+35.3%

Interview Lift

resolved cases with interview

Typical timeline

3y 5m

Avg Prosecution

23 currently pending

Career history

108

Total Applications

across all art units

Statute-Specific Performance

§101

4.3%

-35.7% vs TC avg

§103

29.0%

-11.0% vs TC avg

§102

6.5%

-33.5% vs TC avg

§112

12.4%

-27.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 75 resolved cases

Prosecution Timeline

Sep 02, 2022

Application Filed

Sep 11, 2025

Non-Final Rejection mailed

Mar 10, 2026

Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

18/644,757

Patent 12637521

LOW-VISCOSITY ANTIGEN BINDING PROTEINS AND METHODS OF MAKING THEM

2y 1m to grant Granted May 26, 2026

17/796,416

Patent 12624120

ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF

3y 9m to grant Granted May 12, 2026

17/440,576

Patent 12606602

RECOMBINANT CCN DOMAIN PROTEINS AND FUSION PROTEINS

4y 7m to grant Granted Apr 21, 2026

18/182,827

Patent 12606632

ANTI-CD40 ANTIBODIES AND METHODS OF USE

3y 1m to grant Granted Apr 21, 2026

17/274,834

Patent 12594322

LIQUID COMPOSITION COMPRISING PROTEIN

5y 0m to grant Granted Apr 07, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

68%

Grant Probability

99%

With Interview (+35.3%)

3y 5m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 75 resolved cases by this examiner. Grant probability derived from career allowance rate.